Clinical trials: Incretins
Prediabetes
Cocoa and Metabolic Health in Prediabetes
The purpose of this study is to determine the impact of consuming cocoa on blood glucose levels, glucose metabolism, and other markers of pre-diabetes in overweight and/or obese individuals.
- Trial name
- NCT02203240
- Testing
- Cocoa
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Virginia Polytechnic Institute and State University
Physiology, Gastroenterology
GIP and GLP-1 on Gastric Emptying, Appetite and Insulin-glucose
Academic phase 1 study which investigates the effects of the two incretin hormones glucose-insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) on gastric emptying, appetite, insulin release and glucose disposal in…
- Conditions
- Physiology, Gastroenterology, Endocrinology
- Trial name
- GIP-GLP-gas (NCT01079624)
- Testing
- Glucose-insulinotropic peptide, Glucagon-like peptide-1
- Where
- Sweden
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Uppsala University
Type 2 Diabetes
GLP-1 Mediating DPP-4 Inhibition in Type 2 Diabetes
To determine the extent to which the effects of treatment with LAF237 100 mg QD on glucagon secretion are mediated by Glucagon-like-peptide 1 (GLP-1) in type 2 diabetic patients and healthy subjects.
- Trial name
- NCT02639130
- Testing
- Exendin [9-39]
- Where
- Germany
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Diabeteszentrum Bad Lauterberg im Harz
Obesity, Overweight
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
This is a study of LY3437943 in participants who have obesity or are overweight. The main purpose is to learn more about how LY3437943 affects body weight loss. The study will last about 18 months and may include up to 18 visits.
- Trial name
- NCT04881760
- Testing
- LY3437943
- Where
- 28 sites in United States, Puerto Rico
- Volunteers
- 338 people
- Sponsor
- Eli Lilly and Company
Obesity (BMI>30)
Machine Learning Prediction of Respiratory Muscle Changes and Ventilatory Responses After Incretin-Based Therapy in Obesity
This study aims to evaluate changes in respiratory function, respiratory muscle performance, and ventilatory responses following incretin-based therapy in individuals with obesity, and to identify predictors of these changes…
- Trial name
- NCT07663591
- Testing
- Incretin-based therapy
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Biruni University
Postprandial Lipemia, Type 2 Diabetes
Differential Effects of Milk Proteins on Postprandial Lipemia in Response to a Fat-Rich Meal in Type 2 Diabetes
Enhanced and prolonged postprandial triglyceride responses involve increased cardiovascular risk in type 2 diabetes. It has been demonstrated that dietary fat and carbohydrates profoundly influence postprandial…
- Trial name
- NCT00819975
- Testing
- Casein, Whey Isolate, Whey Hydrolysate
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Aarhus University Hospital
Type 2 Diabetes Mellitus
A Cohort Study of Incretin-based Therapy Combined With Insulin in Type 2 Diabetic Patients for 5 Years
The use of dipeptidyl-peptidase 4 (DPP-4) inhibitors and glucagon like peptide 1 (GLP1) analogues for the treatment of diabetic mellitus (DM) type 2 is growing (1,2).
- Trial name
- NCT01681550
- Testing
- Incretin-based therapy
- Where
- Japan
- Volunteers
- 500 people
- Sponsor
- Nagaoka Red Cross Hospital
Obesity, Postprandial Lipemia
Acute Effects of Dietary Proteins on Postprandial Lipemia, Incretin Responses and Subclinical Inflammation in Obese Subjects
The purpose of this study is to determine the effects of dietary protein on blood lipids and gut hormones after a fat-rich meal.
- Conditions
- Obesity, Postprandial Lipemia, Atherosclerosis, Inflammation
- Trial name
- NCT00863564
- Testing
- Caseine, Cod, Gluten
- Where
- Denmark
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Aarhus University Hospital
Diabetes Mellitus
The Effects of Premeal Consumption of Protein-enriched Bar on Blood Glucose Level and Secretion of Hormones
The aim of this study is to explore premeal protein-enriched bar effect in postprandial glucose levels and concentration of plasma incretin hormones [glucagon-like peptide 1 (GLP-1) and/or glucose-dependent insulinotropic…
- Trial name
- NCT02589028
- Testing
- premeal protein-enriched bar intake, breakfast follows by protein bar
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Obesity & Overweight, Cardiometabolic Conditions
Incretin-based Therapies, Nutrition, and Physical Activity
The goal of this clinical trial is to evaluate whether combining a six-month structured lifestyle intervention (physical activity and nutrition) with incretin-based weight-loss medication improves preservation of muscle mass and…
- Trial name
- HARMONY (NCT07409831)
- Testing
- Intervention, Incretin-Based Treatment
- Where
- 2 sites in Canada
- Volunteers
- 120 people
- Sponsor
- Laval University
Healthy
Physical Training and the Incretin Effect
It is well known that continuous physical exercise leads to a number of changes in the body. Maximal oxygen uptake; the heart's pumping ability and muscle mass and strength increases.
- Trial name
- EXINT2 (NCT01698502)
- Where
- Denmark
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Pancreatectomy; Hyperglycemia
Separate and Combined Extrapancreatic Effects of the Incretin Hormones
The two gut-derived hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) is secreted from intestinal cells in relation to a meal and increase insulin secretion from the pancreas.
- Trial name
- GA-19 (NCT05177653)
- Testing
- Intravenous infusion
- Where
- Denmark
- Volunteers
- 13 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Hyperglycemia, Critical Illness
Stress Hyperglycemia. Potential Role of Incretin Analogs
This is a prospective observational study to examine the levels of glucoregulatory hormones, with special focus on incretins levels, in critically ill patients with stress hyperglycemia.
- Trial name
- NCT01087372
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Hospital Universitari Son Dureta
Metabolic Dysfunction-Associated Steatotic Liver Disease
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease…
- Trial name
- NCT07165028
- Testing
- Tirzepatide, Retatrutide
- Where
- 563 sites in United States, Argentina and 32 more
- Volunteers
- 4,500 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to test the efficacy of once daily saxagliptin in renally impaired patients.
- Trial name
- NCT00614939
- Testing
- Saxagliptin
- Where
- 74 sites in United States, Belarus and 12 more
- Volunteers
- 572 people
- Sponsor
- AstraZeneca
Type 2 Diabetes, Obesity
Changes in Incretins Response and Glycemic Control After Gastric Bypass Surgery in Type 2 Diabetic Patients Versus Healthy
The purpose of this study is to determine the early changes in gut hormonal, and other metabolites with known relations to the glycemic homeostasis.
- Trial name
- NCT01820273
- Where
- Sweden
- Volunteers
- healthy volunteers welcome
- Sponsor
- Lund University
Obesity
Use of Medication to Improve Weight Loss in Suboptimal Early Responders to Behavioral Treatment
This is a two-phase study. Phase 1 will evaluate obesity-related behavioral and biological characteristics as potential predictors of response to behavioral treatment (BT) for weight loss.
- Trial name
- NCT03779048
- Testing
- Behavioral Treatment, Phentermine 15 MG
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- University of Pennsylvania
Type 2 Diabetes
DPP-4 Inhibition, Incretins and Islet Function
Hypothesis is that DPP-4 inhibition affects glucose levels through changes in incretin and islet hormones. The study examines this in relation to breakfast, lunch and dinner over an entire 24h study period by the use of three…
- Trial name
- CODI24 (NCT02089438)
- Testing
- Saxagliptin, Vildagliptin, Sitagliptin
- Where
- Sweden
- Volunteers
- 24 people
- Sponsor
- Lund University
Obesity (BMI>30), Obesity (BMI > 35)
FABP4 Response After Roux-en-Y Gastric Bypass
This retrospective observational cohort study examined serum fatty acid-binding protein 4 (FABP4) dynamics in 28 adults who underwent Roux-en-Y gastric bypass (RYGB), followed at baseline, 3 months, and 6 months.
- Conditions
- Obesity (BMI>30), Obesity (BMI > 35), Insulin Resistance, Bariatric Surgery
- Trial name
- FABP4-RYGB (NCT07774208)
- Volunteers
- 28 people
- Sponsor
- Istanbul University
Type 2 Diabetes
Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D
Objectives: To quantify differences in control of glycemia (primary objective) and the secretion of endogenous incretin hormones (secondary objective) comparing sitagliptin or placebo added to pre-existing therapy with…
- Trial name
- NCT01937598
- Testing
- Mixed meal test, Liraglutide, Sitagliptin
- Where
- Germany
- Volunteers
- 16 people
- Sponsor
- Michael A. Nauck